Business context and reporting period
This is Nanophase Technologies Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2012. The filing describes a nanomaterials developer and manufacturer serving personal care, coatings, polishing, and other markets; its shares traded on OTCQB under NANX. The request metadata names SOLESENCE, INC., which does not match the registrant identified in the filing.
Financial results and liquidity
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Total revenue | $2.409 million | $2.786 million; down 13.5% |
| Product revenue | $2.330 million | $2.706 million; down 13.9% |
| Gross profit / gross margin | $564,000 / 23.4% | $924,000 / 33.2% |
| Operating loss | $780,000 | $555,000 |
| Net loss | $774,000; $0.04 per share | $554,000; $0.03 per share |
| Cash used in operations | $358,000 | $1.601 million |
| Cash and cash equivalents | $2.315 million at March 31 | $2.694 million at December 31, 2011 |
Current assets were $5.469 million and current liabilities $1.404 million at March 31. The company reported no debt; capital lease obligations totaled approximately $31,500. Cash, cash equivalents, and restricted investments totaled $2.345 million. Cash decreased by $378,000 during the quarter. Capital expenditures, including those under capital lease, were $36,794.
Material changes and management commentary
- Product revenue fell primarily because of lower sales in polishing applications. Cost of revenue was nearly flat, reducing gross profit and gross margin.
- Research and development expense was essentially unchanged at $400,000. Selling, general and administrative expense decreased 12% to $944,000, partly due to lower salary, travel, stock compensation, and trade-show costs.
- Management cited improved availability and sharply lower prices for cerium oxide versus 2011 peaks, while warning that rare-earth supply and costs remained important to the polishing business.
- Three customers generated approximately 70%, 10%, and 5% of quarterly revenue, respectively. The largest customer was BASF.
Outlook, risks, and unusual items
- Management expected cash resources and working-capital benefits to fund operating plans through 2012 and into 2013. If identified projects proceed, planned capital spending for the rest of 2012 was estimated at $200,000–$500,000.
- Management anticipated growth from newer markets and customer adoption but said timing and significant revenue from developing applications were uncertain. It did not expect R&D expense to increase significantly in 2012.
- BASF supply agreements include conditions that could give BASF technology-transfer and equipment-purchase rights. One financial trigger involves trailing 12-month earnings below zero together with cash, cash equivalents, and specified investments below $2 million. The company reported approximately $2.345 million in those resources and no debt at quarter-end.
- In April 2012, the Japanese licensee paid a $279,000 advance against a final minimum royalty; the amount was recorded as deferred revenue at March 31 and is to be recognized over the contract term. The related agreement ends March 31, 2013, with territorial restrictions and royalties ending April 1, 2013. The company also assigned the Japanese “NanoTek” trademark for $5,000.
- The company terminated its unused $1 million credit line in March 2012 and voluntarily delisted from Nasdaq, beginning OTCQB trading on March 20. Management warned that loss of an appropriate trading venue could impair access to capital.
- Other risks include customer concentration, potential financing needs, rare-earth supply and pricing, uncertain demand, manufacturing capacity, and potential dilution if new financing is required. The company reported no legal proceedings and stated that disclosure controls were effective.
Important facts for investors to verify
- Confirm the registrant identity: the supplied filing is for Nanophase Technologies Corporation, not SOLESENCE, INC.
- Track cash relative to the $2 million BASF covenant threshold and review the full supply agreements and triggering provisions.
- Assess the concentration and durability of revenue from BASF and the other major customers.
- Verify whether revenue, gross margin, and cash use improve as polishing sales, rare-earth costs, and newer-market adoption evolve.
- Review the Japanese licensee prepayment’s recognition schedule and the expected end of royalty and territorial terms.